Advisory firm EY (Formerly known as Ernst & Young) recently released its analysis of the payer space, EY Progressions 2014: Navigating the Payer Landscape. The short of it is that ACOs and payers have distinct criteria for what makes a drug worthwhile, and pharmaceutical companies are failing to recognize unique payer communication needs. Read more here. (Source: Medical Marketing & Media, 5/7/14).
You are here: / / Is This Drug Worth Covering? Pharma & Payers Not Aligned